Profile change history

What changed for Motixafortide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Motixafortide identity.

17Total events
17Record additions
0Version changes
5Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 17 connected records →

Showing the latest 17 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.

Record added

ClinicalTrials.gov record NCT04543071

PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
September 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05618301

PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
August 11, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06442761

PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
September 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06506461

PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
October 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06547112

PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
August 29, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07101445

PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
July 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07392970

PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.

PeptideScanner change date
November 16, 2026
Cited source date
July 24, 2026
Evidence lane
Clinical trials
Record added

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.

PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 1, 2022
Evidence lane
Literature metadata
Record added

Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.

PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
March 14, 2023
Evidence lane
Literature metadata
Record added

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.

PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

Motixafortide Acetate.

PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2024
Evidence lane
Literature metadata
Record added

A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.

PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 30, 2024
Evidence lane
Literature metadata
Record added

Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.

PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 27, 2025
Evidence lane
Literature metadata
Record added

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.

PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata
Record added

Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.

PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 11, 2026
Evidence lane
Literature metadata
Record added

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.

PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata